Meridia Related Published Studies
Well-designed clinical trials related to Meridia (Sibutramine)
Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). [2008.07.29]
Orlistat and sibutramine beyond weight loss. [2008.06]
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. [2008.05.30]
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. [2008.05]
Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study. [2008.03]
Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. [2008.01]
The effect of sibutramine intake on resting and exercise physiological responses. [2008]
Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. [2007.11]
Orlistat and sibutramine beyond weight loss. [2007.10.08]
Long-term persistence with orlistat and sibutramine in a population-based cohort. [2007.10]
Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. [2007.07]
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. [2007.06.29]
A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders. [2007.06]
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. [2007.04.17]
Long-term persistence with orlistat and sibutramine in a population-based cohort. [2007.04.10]
The effect of sibutramine on energy expenditure and body composition in obese adolescents. [2007.04]
A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. [2007.02]
The effect of sibutramine on energy expenditure and body composition in obese adolescents. [2007.01.30]
Effects of sibutramine on thermogenesis in obese patients assessed via immersion calorimetry. [2006.11]
Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study. [2006.11]
Effects of sibutramine treatment in obese adolescents: a randomized trial. [2006.07.18]
Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. [2006.06.01]
Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. [2006.05]
Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. [2006.05]
[Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial] [2005.09]
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. [2005.08]
Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. [2005.08]
Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program. [2005.07]
Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. [2005.07]
Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure. [2005.06]
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. [2005.05]
Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. [2005.05]
Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. [2005.03]
Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects. [2005.02]
Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine. [2005.02]
Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. [2005.01]
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. [2005.01]
Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study. [2004.12]
Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. [2004.12]
Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. [2004.12]
Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. [2004.10]
Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. [2004.09]
Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. [2004.08]
Comparison of the acute pharmacodynamic responses after single doses of ephedrine or sibutramine in healthy, overweight volunteers. [2004.08]
The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. [2004.06]
The efficacy and safety of sibutramine for weight loss: a systematic review. [2004.05.10]
Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. [2004.05]
Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. [2004.04]
Food intake with an antiobesity drug (sibutramine) versus placebo and rorschach data: a crossover within-subjects study. [2004.04]
Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. [2004.04]
Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? [2004.03]
Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. [2004.03]
Cost-effectiveness of sibutramine in the treatment of obesity. [2004.01]
Pharmacokinetics of sibutramine hydrochloride in Chinese healthy volunteers. [2003.11]
A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. [2003.11]
Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. [2003.11]
Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. [2003.09]
Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. [2003.08]
Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). [2003.08]
Short-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcome. [2003.06]
Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. [2003.05]
Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. [2003.04.09]
Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. [2003.03]
A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. [2003.01]
Paradoxical effect of sibutramine on autonomic cardiovascular regulation. [2002.11.05]
Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. [2002.09]
Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study. [2002.05]
Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. [2002.02]
Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy. [2002.02]
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. [2002.01]
Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. [2002.01]
Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. [2002.01]
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. [2001.11]
Long-term weight loss with sibutramine: a randomized controlled trial. [2001.09.19]
[A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects] [2001.09]
Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. [2001.09]
Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. [2001.06]
[The effect of sibutramine for the maintenance of weight loss. A randomized controlled clinical trial] [2001.05.21]
Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. [2001.05]
[Sibutramine--antidepressive agent tested against obesity] [2001.04.11]
Influence of sibutramine on energy expenditure in African American women. [2001.04]
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. [2001.04]
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. [2000.12.23]
Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. [2000.09]
Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. [2000.07.24]
Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. [2000.06]
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. [2000.04]
A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. [2000.02]
Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. [2000.02]
Modalities of the food intake-reducing effect of sibutramine in humans. [2000.01]
Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. [2000.01]
Abuse liability assessment of sibutramine, a novel weight control agent. [2000.01]
Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. [2000]
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. [1999.10]
The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. [1999.10]
Absence of cardiac valve dysfunction in obese patients treated with sibutramine. [1999.07]
Sibutramine produces dose-related weight loss. [1999.03]
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. [1999.02]
Thermogenic effects of sibutramine in humans. [1998.12]
Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? [1998.08]
A comparison of sibutramine and dexfenfluramine in the treatment of obesity. [1998.07]
|
